Welcome!

News Feed Item

Emulate Launches to Commercialize Automated Human Organs-on-Chips Platform to Accelerate Drug Development, Detect Toxicities and Advance Personalized Medicine

Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. Emulate’s proprietary Organs-on-Chips platform achieves a new industry standard by predicting human responses to medicines, chemicals, and toxins more rapidly and with greater fidelity than animal models. The company’s mission is to commercialize its Organs-on-Chips bioemulation products, automated platform and software to enhance innovation and accelerate the development of pharmaceutical, chemical, cosmetic, and personalized medicine products.

The Emulate, Inc. Lung-on-Chip in the photo is lined with human lung and blood vessel cells to creat ...

The Emulate, Inc. Lung-on-Chip in the photo is lined with human lung and blood vessel cells to create a new living technology platform to emulate human biology (Photo: Business Wire)

“Emulate’s Organs-on-Chips platform provides, for the first time, a window into the inner-workings of human organs without having to invade a living body,” said James Coon, Chief Executive Officer of Emulate. “Our unique automated Organs-on-Chips approach to human bioemulation opens up entirely new possibilities to develop products with enhanced properties, improved efficacy and safety, and personalization to patients and consumers. The company will focus on key strengths of integrating design, biology and engineering to create revolutionary products. We are launching Emulate to be a leader in advancing innovative product design across multiple industries including drug development, healthcare, agriculture and consumer health.”

Emulate will use the proceeds from the financing to advance the first commercial applications of its automated Organs-on-Chips platform through co-innovation with corporate and clinical clients, and through internal development programs. The company’s initial focus will be use of Organs-on-Chips to provide more rapid and accurate evaluation of human responses to drugs and cosmetics, and to create new clinical guidance tools for personalized therapies. The Series A financing was led by the venture capital firm NanoDimension, alongside of investment by Cedars-Sinai Medical Center and private investor Hansjörg Wyss.

“Emulate’s platform has significant potential to advance human health today, not only to better design and evaluate new breakthrough medicines, but also to drive more personalized diagnosis and treatment approaches,” said Shlomo Melmed, M.D., Senior Vice President for Academic Affairs and Dean of the Medical Faculty at Cedars-Sinai. “Our vision is we can one day put each patient’s cells on chips that mimic the function of organs, and this will open up new ways for us to design truly personalized treatment with stem cells, based on each patient’s unique genetic profile on their own individualized Organs-on-Chips.”

Leading Foundational Science and Team

The company’s founding team carried out their ground-breaking foundational research, engineering and technology translation at the Wyss Institute for Biologically Inspired Engineering at Harvard University, which has made automated human Organs-on-Chips a reality. The company’s scientific founder and a pioneer in the field of organs-on-chips, Donald Ingber, M.D., Ph.D., Founding Director of the Wyss Institute and faculty member at Harvard Medical School, Harvard School of Engineering and Applied Sciences, and Boston Children’s Hospital will chair Emulate’s Scientific Advisory board. Lead Senior Staff Scientist at the Wyss Institute, Geraldine A. Hamilton, Ph.D., will join as President and Chief Scientific Officer of Emulate. James Coon, Entrepreneur-in-Residence at the Wyss Institute, has been appointed Emulate’s Chief Executive Officer. Hamilton and Coon collectively have over 30 years of experience in biotechnology startups and the pharmaceutical industry.

Emulate has a worldwide license to a robust and broad intellectual property portfolio for its bioemulation Organs-on-Chips platform from Harvard University, and is uniquely positioned to advance the technology into successful commercial applications, supported by multiple years of vigorous research and development by its experienced team of scientists and engineers.

“This advanced technology is the beginning of a revolution in the way we study human biology and disease, as Emulate sets a new standard for products to be aligned with a complete picture of human biology,” said Geraldine A. Hamilton, Ph.D. “Emulate’s Organs-on-Chips allow living human cells to interact with other cell types within the authentic physical context of living tissues and organs as they would normally in the human body. This ability to bioemulate the human organ microenvironment through microengineering – combined with automated instrumentation that permits molecular scale analysis in real-time – allows us to replicate, analyze and predict human responses in a truly unique and powerful way.”

Organs-on-Chips for Human Bioemulation

Emulate’s technology represent a unique human bioemulation platform that permits analysis of molecular functions within human cells living in an engineered microenvironment that accurately recapitulates human organ biology. Human Organs-on-Chips are miniaturized devices created with microchip manufacturing that contain tiny hollow channels lined by living human cells and tissues cultured under continuous fluid flow and mechanical forcing regimens, such as cyclic breathing and peristalsis, which effectively recapitulate organ-level physiology and disease responses. In Emulate’s automated platform, different Organs-on-Chips, such as lung, liver, intestine, kidney, skin, eye, and blood-brain-barrier, can be linked together by flowing liquid containing living human immune cells that simulates blood to form a “Human-Body-on-Chips” to more closely replicate whole body-level responses.

About Emulate

Emulate, Inc. is a private company focused on commercializing Organs-on-Chips as an automated human bioemulation platform that achieves a new standard for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate is advancing product innovation, design and safety across a range of applications in drug development, personalized medicine, agriculture and chemical-based consumer products. For more information, visit www.emulatebio.com.

About NanoDimension

NanoDimension is a U.S. and Europe based venture capital firm specializing in nanotechnology. Founded in 2002, NanoDimension invests in early-stage companies that are developing break-through technologies at the nano-scale to disrupt markets and to solve critical global problems. For more information, visit www.nanodimension.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While many government agencies have embraced the idea of employing cloud computing as a tool for increasing the efficiency and flexibility of IT, many still struggle with large scale adoption. The challenge is mainly attributed to the federated structure of these agencies as well as the immaturity of brokerage and governance tools and models. Initiatives like FedRAMP are a great first step toward solving many of these challenges but there are a lot of unknowns that are yet to be tackled. In hi...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
The proper isolation of resources is essential for multi-tenant environments. The traditional approach to isolate resources is, however, rather heavyweight. In his session at 18th Cloud Expo, Igor Drobiazko, co-founder of elastic.io, drew upon his own experience with operating a Docker container-based infrastructure on a large scale and present a lightweight solution for resource isolation using microservices. He also discussed the implementation of microservices in data and application integrat...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of Dev...
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
"LinearHub provides smart video conferencing, which is the Roundee service, and we archive all the video conferences and we also provide the transcript," stated Sunghyuk Kim, CEO of LinearHub, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.